Eli Lilly says its new once-daily pill, orforglipron, helped people lose significant weight and lower blood sugar in a late-stage clinical trial. The company plans to seek global regulatory approval later this year. The study included people with overweight, obesity and type 2 diabetes. Participants who took the highest dose of the drug (36 milligrams)… read on > read on >







